|
Q4 FY2026
As of Jun 30, 2026
|
Q3 FY2026
As of Mar 31, 2026
|
Q2 FY2026
As of Dec 31, 2025
|
Q1 FY2026
As of Sep 30, 2025
|
Q4 FY2025
As of Jun 30, 2025
|
Q2 FY2025
As of Dec 31, 2024
|
Q1 FY2025
As of Sep 30, 2024
|
Q4 FY2024
As of Jun 30, 2024
|
Q3 FY2024
As of Mar 31, 2024
|
Q2 FY2024
As of Dec 31, 2023
|
Q1 FY2024
As of Sep 30, 2023
|
Q4 FY2023
As of Jun 30, 2023
|
Q3 FY2023
As of Mar 31, 2023
|
Q2 FY2023
As of Dec 31, 2022
|
Q1 FY2023
As of Sep 30, 2022
|
Q4 FY2022
As of Jun 30, 2022
|
Q3 FY2022
As of Mar 31, 2022
|
Q2 FY2022
As of Dec 31, 2021
|
Q1 FY2022
As of Sep 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and due from banks | |||||||||||||||||||
| Interest-bearing deposits | |||||||||||||||||||
| Total cash and cash equivalents | |||||||||||||||||||
| Long-term certificates of deposit | |||||||||||||||||||
| Securities available-for-sale, at fair value | |||||||||||||||||||
| Securities held-to-maturity, at amortized cost, net of allowance for credit losses of $530 and $548 | |||||||||||||||||||
| Equity securities, at fair value | |||||||||||||||||||
| Federal Home Loan Bank stock, at cost | |||||||||||||||||||
| Loans receivable | |||||||||||||||||||
| Allowance for credit losses on loans | |||||||||||||||||||
| Unearned origination fees and costs, net | |||||||||||||||||||
| Net loans receivable | |||||||||||||||||||
| Premises and equipment, net | |||||||||||||||||||
| Bank-owned life insurance | |||||||||||||||||||
| Accrued interest receivable | |||||||||||||||||||
| Foreclosed real estate | |||||||||||||||||||
| Prepaid expenses and other assets | |||||||||||||||||||
| Total assets | |||||||||||||||||||
| LIABILITIES AND SHAREHOLDERS’ EQUITY | |||||||||||||||||||
| Noninterest-bearing deposits | |||||||||||||||||||
| Interest-bearing deposits | |||||||||||||||||||
| Total deposits | |||||||||||||||||||
| Borrowings, short-term | |||||||||||||||||||
| Borrowings, long-term | |||||||||||||||||||
| Subordinated notes payable, net | |||||||||||||||||||
| Accrued expenses and other liabilities | |||||||||||||||||||
| Total liabilities | |||||||||||||||||||
| SHAREHOLDERS' EQUITY | |||||||||||||||||||
| Preferred stock, Authorized - 1,000,000 shares; Issued - None | |||||||||||||||||||
| Common stock, par value $0.10 per share; Authorized - 36,000,000 shares; Issued – 17,222,680 shares; Outstanding – 17,025,485 and 17,026,828 shares | |||||||||||||||||||
| Additional paid-in capital | |||||||||||||||||||
| Retained earnings | |||||||||||||||||||
| Accumulated other comprehensive loss | |||||||||||||||||||
| Treasury stock, at cost – 197,195 and 195,852 shares | |||||||||||||||||||
| Total shareholders’ equity | |||||||||||||||||||
| Total liabilities and shareholders’ equity | |||||||||||||||||||
Loading...
